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Abstract The clinical venous thromboembolism (VTE) pattern often showswideheterogeneitywithin
relatives of a VTE-affected family, although they carry the same thrombophilia defect. It is
then mandatory to develop additional tools for assessing VTE risk in families with
thrombophilia. This study aims to assess whether common environmental and genetic
risk factors for VTE contribute to explain this heterogeneity. A total of 2,214 relatives from
651 families with known inherited thrombophilia were recruited at the referral center for
thrombophilia in Marseilles, France, from 1986 to 2013. A thrombophilia screening was
systematically performed in all included relatives. According to the severity of the
thrombophilia defect, individuals were split into three groups: no familial defect, mild
thrombophilia, and severe thrombophilia. In addition, common genetic factors (ABO blood
group and 11 polymorphisms selected on the basis of their association with VTE in the
general population) were genotyped. Furthermore, body mass index and smoking were
collected. VTE incidence was 1.74, 3.64, and 6.40 per 1,000 person-years in individuals with
no familial defect,mild thrombophilia, and severe thrombophilia, respectively. Five common
risk factorswere associatedwith VTE in this population: obesity, smoking, ABObloodgroup,
and F11_rs2036914 and FGG_rs2066865polymorphisms. These common factorswere then
included into a three-level risk score. The score was highly efﬁcient for assessing VTE risk in
mild thrombophilia patients by identifying two groups with different VTE risk; individuals
with low score had the same risk as individuals with no familial defect whereas individuals
with high score had the same risk as individuals with severe thrombophilia. An overall score
including the ﬁve items plus the thrombophilia status was built and displayed an area under
the receiver operating characteristic curve of 0.702 for discriminating VTE and non-VTE
relatives. In conclusion, integrating common environmental and genetic risk factors
improved VTE risk assessment in relatives from families with thrombophilia.
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Introduction
Venous thromboembolism (VTE), including deep vein
thrombosis (DVT) and pulmonary embolism (PE), is the third
cause of cardiovascular death.1 The genetic part plays an
important role as the heritability of VTE has been assessed to
be 50 to 60%.2–4 In clinical practice, when an inherited
disorder is suspected a thrombophilia testing consisting of
the search for the ﬁve following defects is performed:
antithrombin (AT), protein C (PC) and protein S (PS) deﬁ-
ciencies, factor V Leiden (FVL), and the G20210A prothrom-
binmutation (PTM).5When a defect is diagnosed in a patient
with a personal history of VTE, testing of family members is
often performed to aid decision-making regarding future
VTE prophylaxis in at-risk situations. However, usefulness of
thrombophilia testing in assessing individual risk in families
with inherited thrombophilia is largely debated as it does not
properly assess the individual risk within a family.6,7 Indeed,
the test results do not clearly dichotomize carriers and
noncarriers in terms of risk for a ﬁrst episode of VTE. As a
consequence, relatives harboring the family defect are
usually considered at high risk, no matter the severity of
the thrombophilia. Thus, the prevention strategy is mostly
based on the result of the thrombophilia testing probably
leading to an overprevention in particular in mild thrombo-
philia carriers (i.e., heterozygosity for FVL or PTM). On the
contrary, relatives with a negative thrombophilia testing are
often falsely considered at low risk.
The assessment of VTE risk in families with known
inherited thrombophilia needs to be improved by acquiring
more insight into the genetic and environmental risk factors.
Other factors may then be taken into consideration when
assessing individual risk. These could include both additional
genetic risk factors muchmore common than those involved
in the thrombophilia testing and environmental factors, the
two main being obesity and smoking.8–11 Assessment of
obesity and smoking on the risk of VTE in families with
known thrombophilia has never been performed yet.
The aim of the present study is to evaluate the inﬂuence of
smoking, obesity, and newly identiﬁed common genetic
factors on VTE risk in families with known thrombophilia
with the ultimate goal of improving VTE risk assessment in
family members.
Methods
Patients
Investigated families were part of the MARseilles FAmily
Study on venous Thrombosis (MARFAST). The original MAR-
FAST cohort has been extensively described previously.12
Brieﬂy, families were recruited between 1986 and 2008 at
the referral center for thrombophilia in Marseilles, France. A
familywas included in theMARFAST cohort if it comprised at
least two members with the following characteristics: one
individual with a personal history of conﬁrmed VTE and a
positive thrombophilia testing (the proband) and a relative
harboring the same defect (regardless his/her VTE history).
All relatives referred to the center for thrombophilia were
then included. Relatives were classiﬁed as ﬁrst-degree rela-
tives if they were a biological child or parent, or full sibling.
Otherwise, they were considered as second-degree relatives.
VTE was deﬁned as a DVT and/or a PE. Superﬁcial vein
thrombosis was not included. A VTE episode was conﬁrmed
if objectively diagnosed by medical imaging: compression
ultrasound, venography, ventilation/perfusion lung scan,
spiral computed tomography or pulmonary angiography;
or if the patient received full-dose anticoagulation for at
least 3 months. A thrombophilia testing was systematically
performed in all included relatives. Relatives were classiﬁed
into three classes according to the severity of the thrombo-
philia: no familial defect, mild thrombophilia (FVL hetero-
zygosity or PTM heterozygosity), and severe thrombophilia
(AT, PC, PS deﬁciencies, FVL homozygosity, PTM homozyg-
osity, and combined defects). The present study is an exten-
sion of the MARFAST cohort. The inclusions, using the same
criteria, have been extended until 2013 at the same center.
This MARFAST update included a total of 2,214 relatives
(including 1,492 ﬁrst-degree relatives) from 651 families,
representing 151 more families and 940 more relatives than
the previous analysis.
Variables
A standardized questionnaire allowed the collection of clin-
ical data during the consultation by a trained physician. The
age, localization, and the triggering circumstances of VTE
episodes were collected. A VTE episode was considered
provoked if associated with an exposure within 3 months
to exogenous risk factors: surgery, immobilization deﬁned as
bed conﬁnement for at least 7 days, trauma, pregnancy,
puerperium, combined oral contraceptive use, or malig-
nancy. Otherwise, the episode was deﬁned as unprovoked.
The body mass index (BMI) was calculated during the con-
sultation. Relatives were classiﬁed into three classes of BMI:
<30 kg/m2, 30 to 35 kg/m2, and >35 kg/m2, based on the
WHO classiﬁcation of obesity. The smoking status, deﬁned as
current smoking (one cigarette per day) or nonsmoking,
was determined either at the time of the episode for VTE
relatives or at the time of the consultation for relatives with
no personal history of VTE. Former smokers were classiﬁed
as nonsmokers.
The characteristics of the probands were collected: age at
the time of VTE and triggering circumstances at the time of
ﬁrst VTE. A thrombophilia testing was systematically per-
formed in all relatives: AT, PC, and PS levelsweremeasured as
previously described and FVL and PTM were genotyped
using light cycler technology (Roche Diagnostics, Indianapo-
lis, Indiana, United States).12 ABO blood group was geno-
typed and classiﬁed into three categories according to the
level of risk previously estimated: A/B, AB, and O. The
previous MARFAST investigation mainly relied on well-
established risk factors for VTE and measurable coagula-
tion-related biomarkers. Only three single nucleotide poly-
morphisms (SNPs) had been previously investigated in
MARFAST, the F11 polymorphisms (rs2036914 and
rs2289252) and the FGG8_rs2066865. We here investigated
the impact of eight additional SNPs whose association with
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VTE was supported by recent genome-wide association
studies (GWASs): F2_rs3136516, F5_rs4524, KNG1_710446,
PROCR_rs867186 and rs2069951, SERPINC1_rs2227589,
SLC44A2_rs2288904, and TSPAN15_rs78707713.
Statistical Analysis
Probands were excluded for the statistical analysis. First, a
descriptive analysis was performed. Quantitative variables
were described using means and standard deviations, and
categorical variables were described using numbers and per-
centages. Comparisons of major clinical characteristics
between VTEþ and VTE– groups were performed using chi-
square test or Fisher’s test when appropriate for categorical
variables, and using Student’s t-test or Mann–Whitney test
when appropriate for quantitative variables. The incidence rate
ofVTEwasestimatedbydividing thenumberofVTEby thesum
of the observation time for all participants. The observation
timewasdeﬁned as the period frombirthuntil theﬁrst episode
of VTE for participants who presented a VTE, or until the age at
the visit for those who did not present a VTE episode. The
incidence rate was expressed as number per 1,000 person-
years (p-y). Univariate time-to-event analysis was ﬁrst per-
formed to assess the association between the risk of VTE over
timeandclinical andbiological characteristics.ACoxregression
model was used, including a frailty term to handle the family
structure of the data (family identiﬁer as a random effect).
Multivariate analyses were then performed to simulta-
neously integrate all characteristics that were associated with
the riskofVTEwithap-value < 0.15according to theunivariate
analyses. A multivariate frailty Cox model was built using a
backward selection procedure to retain signiﬁcant variables
(p < 0.05) and estimate adjusted hazard ratios (aHRs) with
their 95% conﬁdence interval (CI). The proportional hazards
assumptionwas assessed by testing covariate interactionswith
quadratic function of time and checked graphically using
Schoenfeld-type residuals. According to the value of the
adjusted parameters (log HRs), a score of VTE risk was estab-
lished by attributing 0, 1, or 2 points for each modality of the
characteristics included in the ﬁnal multivariate model. The
incidence rateofVTEand its95%CIwereestimatedaccording to
this score to assess its validity. A receiver operating character-
istic (ROC) curve was used to assess the global discriminative
performances of the various explored scores, to distinguish
VTEþ from VTE– patients. The area under the curve was
estimated, with its 95% CI. Patients with missing data were
excluded from the multivariate analysis.
All tests were two-sided. All p-values < 0.05 were con-
sidered signiﬁcant. All analyses were performed with the R
software.
All participants gave written informed consent, and the
study met all institutional ethics requirement. The proce-
dures employed were reviewed by the Assistance Publique
des Hopitaux de Marseille institutional review committee.
Results
A total of 2,214 relatives from 651 families were included.
More than 60% of relatives had a positive thrombophilia
testing, of whom43.8 and 17.2% harbored amild and a severe
thrombophilia, respectively (►Supplementary Table S1). As
expected, FVL was the most prevalent thrombophilia defect
with a prevalence of 30.8% in relatives.
Main characteristics of the relatives according to VTE
status are shown in►Table 1. In total, 246 (11.1%) presented
with a VTE history. Among them, 113 had had an unprovoked
episode (45.9%). The mean age at the end of the follow-up
was 41.7 and 31.9 years (p < 0.001) for VTE and VTE-free
relatives, respectively.
Environmental Risk Factors
Grade 1obesity deﬁned as aBMIbetween30and35kg/m2and
grade 2 obesity deﬁned as a BMI above 35 kg/m2 were
associated with an increased risk of VTE. The incidence rate
ofVTEwas3.03per1,000p-y fornonobese relatives (BMI < 30
kg/m2), 6.38 per 1,000 p-y for relatives with grade 1 obesity,
and 6.05 per 1,000 p-y for relatives with grade 2 obesity. As
grade 1 and grade 2 incidences were comparable, the two
categories were merged into one category of obese relatives
(BMI > 30 kg/m2) for further analyses. The overall incidence
rate for obesitywas thus6.30per 1,000p-y (95%CI, 4.63–8.36).
The incidence rate was 3.19 per 1,000 p-y (95% CI, 2.74–
3.69) and 4.00 per 1,000 p-y (95% CI, 3.11–5.07) for non-
smokers and smokers, respectively.
Characteristics of First VTE in Probands
Neither the age nor the absence of triggering circumstances
at the time of the VTE in probandswas associatedwith VTE in
relatives: 24.4% of VTE– relatives and 28.4% of VTEþ relatives
had a proband with a history of VTE at a young age (<45
years) (p ¼ 0.19), and 60.5% of VTE– relatives and 60.6% of
VTEþ relatives had a proband with a history of unprovoked
VTE (p ¼ 0.94) (data not shown).
Conventional Genetic Risk Factors
A thrombophilia was diagnosed in 76.1% of VTEþ relatives,
whereas only 59% of VTE– relatives harbored a thrombophi-
lia defect, the difference holding mainly in severe thrombo-
philia (30.5 vs 15.5%). The incidence rate of VTE increased
with the severity of the thrombophilia defect: 1.74, 3.64, and
6.40 per 1,000 p-y in relatives with no defect, mild, and
severe thrombophilia, respectively.
The incidence rate of VTE greatly varied according to the
blood group, the highest incidence ratebeing observed for AB
blood group relatives. Incidence rates were 2.29 per 1,000 p-
y (95% CI, 1.71–2.99), 3.58 per 1,000 p-y (95% CI, 3.03–4.19),
and 6.15 per 1,000 p-y (95% CI, 3.98–9.06) for O, A/B, and AB
relatives, respectively.
Genetic Polymorphisms Recently Identiﬁed as Risk
Factors for VTE
►Table 2 shows theresultsof thegenotypingof the11selected
polymorphisms. Three SNPs, F11_rs2036914 (p ¼ 0.003),
FGG_rs2066865 (p ¼ 0.015), and F11_rs2289252 (p ¼ 0.036),
were signiﬁcantly associated with VTE risk.
A score combining all common genetic risk factors (11
polymorphisms þ ABO blood group) was tested. Its
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predictive performance assessed according to the area under
the receiver operating characteristics curve (AUC) was poor
(AUC ¼ 0.573; 95% CI, 0.529–0.616).
Multivariate Analysis
Themultivariate analysis comprised the thrombophilia status,
obesity, smoking status, ABO blood group, FGG_rs2066865,
F11_rs2036914, and F11_rs2289252, and a systematic adjust-
ment for gender. The results are shown in ►Table 3.
In the multivariate model, the highest aHR was observed
for severe thrombophilia (aHR ¼ 3.78 [95% CI, 2.49–5.73]).
Among common risk factors, blood group AB and current
smoking were associated with the highest levels of risk
(aHR ¼ 2.51 [95% CI, 1.50–4.22] and 2.08 [95% CI, 1.51–
2.86], respectively). Obesity was associated with a 1.78-
fold increase of VTE (95% CI, 1.24–2.55).
Only two SNPs remained signiﬁcant in the multivariate
model, FGG_rs2066865 and F11_rs2036914. The presence of
at least one at risk allele was associated with an increased
risk of VTE: aHR¼ 1.55 (95% CI, 1.06–2.26) and 1.61 (95% CI,
1.21–2.13) for F11_rs2036914 (p ¼ 0.001) and
FGG_rs2066865 (p ¼ 0.023), respectively.
Interactions between all genetic and environmental fac-
tors selected for the multivariate analysis were tested. None
were signiﬁcant at a 0.05 threshold.
A risk stratiﬁcationwas thenperformed taking into account
the ﬁve common risk factors for VTE: F11_rs2036914,
FGG_rs2066865, ABO blood group, obesity, and smoking
status.
Observed HRs for the different components of the score
being equally important, a simpliﬁed scoring method was
applied: relativeswere scored 0 or 1 point for each parameter
but ABO. The scoring system was slightly different for ABO
blood group because of the variety of ABO proﬁles and their
associated HR: 0 for O blood group, 1 for A or B blood group,
and 2 for AB blood group. After calculating the overall score,
theoretically spanning from 0 to 6, relatives were classiﬁed
into three groups: 0–1 point; 2 points; and 3 points or more.
The VTE incidence ratewas calculated in the three categories
of risk in all relatives or according to the thrombophilia status
(►Fig. 1; ►Supplementary Table S2).
A trend toward an increased incidence rate was
observed according to the score: 1.30, 2.94, and 4.95 per
1,000 p-y in low-, medium-, and high-risk relatives, respec-
tively (p < 0.0001) (►Fig. 1;►Supplementary Table S2). This
observation held in all thrombophilia categories (p ¼ 0.04,
< 0.0001, and 0.002 for no defect, mild, and severe throm-
bophilia, respectively). The combination of the information
on this risk score together with the result of the thrombo-
philia testing led to an annual incidence rate ranging from
0.60 per 1,000 p-y for the combination of no defect and low
risk score (score ¼ 0 or 1) to 9.85 per 1,000 p-y for the
combination of severe thrombophilia and high risk score
(score 3) (►Fig. 1; ►Supplementary Table S2). It is note-
worthy that the observed incidences in the mild thrombo-
philia group were quite heterogeneous in terms of risk. On
the one hand, relatives with combination of mild thrombo-
philia/low risk score had a 0.91 per 1,000 p-y incidence,
which was comparable to the combination of no familial
defect/low risk score (0.60 per 1,000 p-y). On the other hand,
relatives with combinations of mild thrombophilia/high risk
score and severe thrombophilia/medium risk score displayed
Table 1 Main characteristics of the relatives according to the VTE status
Variable VTEþ (n ¼ 246) VTE– (n ¼ 1,968) p
Female sex (%) 153 (62.2) 1,189 (60.4) 0.59
Mean follow-up, in years (SD) 41.7 (16.8) 31.9 (17.3) < 0.0001
Thrombophilia screening
No defect (%) 58 (23.6) 807 (41.0) < 0.0001
Mild thrombophiliaa (%) 113 (45.6) 856 (43.5)
Severe thrombophiliab (%) 75 (30.5) 305 (15.5)
ABO blood group
A or B (%) 154 (66.4) 1,134 (60.0) < 0.0001
AB (%) 25 (10.8) 99 (5.2)
O (%) 53 (22.8) 657 (34.8)
BMI < 30 kg/m2 (%) 178 (79.1) 1,621 (93.0) < 0.0001
BMI ¼ 30–35 kg/m2 (%) 36 (16.0) 91 (5.2)
BMI > 35 kg/m2 (%) 11 (4.9) 31 (1.8)
Current smoking (%) 68 (27.6) 453 (23.1) 0.11
First VTE episode ¼ PE ( DVT) (%) 53 (21.5) – –
Unprovoked VTE 113 (45.9) – –
aMild thrombophilia: factor V Leiden heterozygosity or prothrombin mutation heterozygosity.
bSevere thrombophilia: antithrombin, protein C, protein S deﬁciencies, factor V Leiden homozygosity, prothrombin mutation homozygosity, and
combined defects.
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very similar incidences (4.98 and 4.83 per 1,000 p-y,
respectively).
We then performed an overall time-to-event analysis
taking into account both score and thrombophilia status,
indicating that the observed effects were independent.
Medium and high risk scores were associated with aHR of
2.31 (1.35–3.97) and 4.23 (2.54–7.04), respectively (global p-
value < 0.0001), as compared with low risk score. Similarly,
mild and severe thrombophilia were associated with aHR of
2.02 (1.38–2.95) and 3.88 (2.58–5.87), respectively (global p-
value < 0.0001), as compared with no defect.
An overall predictive score including both common risk
factors and the thrombophilia status was built. The ranking
of common risk factors was the same as previously men-
tioned. One point was attributed for mild thrombophilia and
3 points for severe thrombophilia, according to the observed
aHR in the multivariate analysis. The 6-item score demon-
strated a good performance with an AUC of 0.702 (95% CI,
0.666–0.739). The ROC curve is shown in►Fig. 2. A subgroup
analysis was then performed according to the triggering
circumstances of the VTE episode. Similar results were
obtained in both provoked and unprovoked episodes with
respective AUC of 0.705 (95% CI, 0.656–0.754) and 0.728 (95%
CI, 0.679–0.777) (►Supplementary Figs. S1 and S2).
The analysis was then performed according to the degree
of kinship. Similar effects were observed when focusing the
analysis in ﬁrst-degree relatives only (data not shown).
Discussion
Five common genetic and environmental factors were
associated with VTE in families with thrombophilia:
F11_rs2036914, FGG_rs2066865, ABO blood group, obesity,
and smoking status. VTE risk assessment in families with
heritable thrombophilia remains a major issue as relatives
with no known defect harbor a two- to threefold increased
risk of VTE compared with the general population and the
vast majority of patients with a mild thrombophilia will not
ever undergo a VTE episode.13–15 This suggests that con-
sidering the familial defect testing only for assessing the
individual risk in relatives is probably coarse. The assessment
of VTE risk in families with inherited thrombophilia needs to
be improved. This could be done by measuring the impact of
common environmental and genetic risk factors. Although
VTE is a complex disease, its environmental part has not been
assessed in families with heritable thrombophilia. Among
environmental risk factors, obesity and smoking are highly
prevalent. Obesity is a well-established risk factor for VTE,
Table 2 Genotyping of 11 selected SNPs reported to be associated with VTE
SNP Risk allele Genotype VTEþ VTE– pa
FGG rs2066865 T CC 102 1,005 0.015
CT-TT 112 777
F11 rs2036914 C TT 37 470 0.003
CT-CC 178 1,310
F11 rs2289252 T CC 48 522 0.036
CT-TT 162 1,230
F5 rs4524 A GG 5 65 0.307
GA-AA 214 1,729
SLC44A2 rs2288904 G AA 12 103 0.882
AG-GG 204 1,671
TSPAN15 rs78707713 T CC 0 22 0.161
CT-TT 224 1,799
PROCR rs867186 G AA 180 1,478 0.881
AG-GG 38 321
F2 rs3136516 G AA 86 628 0.211
AG-GG 131 1,150
PROCR rs2069951 A GG 191 1,585 0.886
GA-AA 26 209
SERPINC1 rs2227589 A GG 154 1,364 0.491
GA-AA 44 344
KNG1 rs710446 T CC 41 357 0.702
CT-TT 183 1,486
Abbreviations: SNP, single nucleotide polymorphism; VTE, venous thromboembolism.
ap-Value calculated using a chi-square test.
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whereas the relation between smoking and VTE has been
debated for many years.8,9 However, during the past 5 years,
two large meta-analyses have been performed in the general
population and reached the same conclusion that smoking is
associated with VTE.10,11 Compared with never smokers, the
relative risk for current smokers was found to be about 1.2
both in the Cheng et al and Mahmoodi et al studies,
respectively.10,11
In the present study, we demonstrated that both com-
mon environmental and genetic factors modiﬁed the risk of
VTE in families with thrombophilia. To the best of our
knowledge, our study reports for the ﬁrst time the inci-
dence rate associated with obesity and smoking in families
with thrombophilia. Obesity and smoking appeared to be
signiﬁcant predictors for VTE with associated HR of
approximately 2. We here conﬁrmed the association
between smoking and increased VTE risk, with a slightly
higher risk (2.1) observed in thrombophilia families. Very
interestingly, the risk associated with these two environ-
mental and thus modiﬁable factors was comparable to the
risk associated with the presence of mild thrombophilia
(HR, 1.9).
Table 3 Disease-free survival multivariate analysis with adjustment for age and gender and attributed score
Variables n (%) Hazard ratio
(95% CI)
p-Value Attributed score
No familial defect 647 (37.4) 1 – –
Mild thrombophilia 794 (45.9) 1.91 (1.30–2.80) < 0.0001 –
Severe thrombophilia 290 (16.8) 3.78 (2.50–5.73) < 0.0001 –
BMI < 30 kg/m2 1,589 (91.8) 1 – 0
BMI > 30 kg/m2 142 (8.2) 1.78 (1.24–2.55) 0.002 1
No smoking 1,306 (75.4) 1 – 0
Current smoking 425 (24.6) 2.08 (1.51–2.86) < 0.0001 1
Blood group O 565 (32.6) 1 – 0
Blood group A or B 1,068 (61.7) 1.37 (0.98–1.93) 0.067 1
Blood group AB 98 (5.7) 2.51 (1.50–4.22) 0.005 2
F11 rs2036914–TT 418 (24.1) 1 0
F11 rs2036914–CT/CC 1,313 (75.9) 1.55 (1.06–2.26) 0.023 1
FGG rs2066865–CC 957 (55.3) 1 – 0
FGG rs2066865–CT/TT 774 (44.7) 1.61 (1.21–2.13) 0.001 1
Fig. 1 VTE incidence according to the score and the thrombophilia
status. The score is calculated on the basis of ﬁve items: obesity
according theWHO deﬁnition (BMI > 30 kg/m2), smoking status, ABO
blood group, F11 rs2036914, and FGG rs2066865.
Fig. 2 ROC curve of the risk score combining ﬁve common factors and
the thrombophilia status. AUC ¼ 0.702 (95% conﬁdence interval,
0.666–0.739).
TH Open Vol. 3 No. 1/2019
Venous Thromboembolism Risk in Families Suchon et al. e33
The characteristics of the probands’ ﬁrst VTE did not
modulate VTE risk in relatives. These results differ somewhat
with previous publication in which thrombosis at young age
and unprovoked VTE in probands predict VTE in relatives.16
However, only FVL and PTM were analyzed in this study and
the vast majority of probands had no familial defect.
Among common genetic risk factors, we conﬁrmed the
previous results observed in the MARFAST study.17 In the
present extended MARFAST study, ABO blood group,
F11_rs2036914, and FGG_rs2066865 were associated with
HR ranging from1.5 for F11_rs2036914 to 2.5 for bloodgroup
AB. Interestingly, F11_rs2036914 and FGG_rs2066865 are
located in genes related to the coagulation cascade. They
were previously reported to associate with plasma levels of
the corresponding factors: the factor XI and the ﬁbrinogen,
respectively.18,19 Of note, the latter is actually associated
with a subunit of ﬁbrinogen, the ﬁbrinogen gamma, whose
low levels were further demonstrated to associate with
venous thrombosis. This opens the question of the clinical
interest of measuring factor XI and ﬁbrinogen gamma in
families with thrombophilia.
To improve the assessment of VTE risk in families with
inherited thrombophilia, we here proposed an effective
additional tool based on the ﬁve common risk factors asso-
ciated with VTE within the MARFAST families: smoking,
obesity, ABO blood group, F11_rs2036914, and
FGG_rs2066865. These ﬁve factors were then combined
into a predictive score, which allowed the stratiﬁcation of
the risk in relatives, and then classiﬁed in low, medium, and
high risk score patients. When considering the thrombophi-
lia status only, the incidence ratewas 1.74 per 1,000 p-y, 3.64
per 1,000 p-y and 6.40 per 1,000 p-y for no defect, mild
thrombophilia and severe thrombophilia groups, respec-
tively, whereas it actually ranged from 0.60 to 9.85 per
1,000 p-y when combining the thrombophilia testing and
the risk score. Thus, the highest incidence observed in
relatives with severe thrombophilia was not high enough
for indicating primary prevention for VTE (VTE risk < bleed-
ing risk under anticoagulant). As a consequence, such a score
could not be used for identifying individuals that should
beneﬁt from primary prevention. On the contrary, the score
is promising for identifying low-risk individuals. The asser-
tion mainly holds in mild thrombophilia relatives. Even if
most of them will remain disease-free, mild thrombophilia
carriers are often considered at increased risk of VTE, in the
absence of efﬁcient tool. In this group of individuals, the
global incidence rate was 3.64 per 1,000 p-y, whereas it
actually ranged from 0.91 to 4.98 per 1,000 p-y according to
the stratiﬁcation. Very interestingly, the stratiﬁcation iden-
tiﬁed 21% of the relatives harboring a low risk and an
incidence rate comparable to the general population (0.91
vs. 1 per 1,000 p-y).20,21 Similarly, 23% of no-defect relatives
had low risk score and displayed a 0.60 per 1,000 p-y
incidence. Altogether, the score could discriminate relatives
with no defect or mild thrombophilia with “standard” VTE
risk. The identiﬁcation of those relatives could have positive
impacts. For instance, combined oral contraceptives are
contraindicated in mild thrombophilia carriers in most
recommendations, whereas for some authors combined
oral contraceptives could be used in the absence of additional
risk factors.22 It would be interesting to test this score in this
speciﬁc population as individuals with low risk score might
beneﬁt from combined oral contraceptives use. Moreover,
the score identiﬁed a group of relatives with no familial
defect displaying a higher risk than the general population
(incidence ¼ 2.62 per 1,000 p-y). This former group of
individuals might beneﬁt from VTE prevention in at-risk
situations. Of note, even if relatives with severe thrombo-
philia displayed a great amplitude of risk (incidence rate
ranging from 3.44 to 9.85 per 1,000 p-y) according to the
score, this stratiﬁcation could not discriminate a group of
relatives at low risk. As a consequence, those relatives with
severe thrombophilia should probably be considered as a
homogenous group of patients with a high risk of VTE
according to most recommendations and thus beneﬁt from
prevention in at-risk situations. We further showed that the
proposed score based on common risk factors was indepen-
dent of the result of the thrombophilia testing, suggesting
that it adds some valuable information for assessing the risk
in relatives from families with known thrombophilia.
The performance of the overall score combining ﬁve
common risk factors and the thrombophilia status was
assessed. The AUC was 0.702 (95% CI, 0.666–0.739). Such
predictive scores for VTE have been built in the general
population.23–25 However, only the score published by de
Haan et al could be tested in our study according to the
available data. It is a ﬁve-SNP risk score including three
common SNPs (rs2036914 for ABO blood group,
FGG_rs2066865, F11_rs2036914), FVL, and PTM. The score
displayed 0.69 and 0.67 AUC in the MEGA study and the
Leiden Thrombophilia Study, respectively.23 In our cohort,
the AUC of the de Haan score was 0.634 (95% CI, 0.594–
0.675), which was slightly less than our proposed score that
additionally integrates two common environmental risk
factors (obesity and smoking) and severe thrombophilia.
To the best of our knowledge, the present study is one of
the largest family studies on inherited thrombophilia pub-
lished so far. However, this study shows some limits. In ﬁrst
instance,missing data led to a loss of power. Indeed, only 197
relatives with VTE could be tested out of the 242 included
because of missing data, predominant on BMI (21 relatives).
This lack of power could explain the absence of association
between SNPs recently identiﬁed in GWASs and VTE in the
families. In addition, we conducted a single-center study,
which limits the generalizability of the results. An external
validation study is mandatory. Another limitation of the
study is the difference between VTE-free and VTEþ patients
in terms of duration of follow-up (respectively, 32 and 42
years). However, the chosen analysis required to hypothesize
that the censorship was not informative (time-to-event
analysis based on likelihood). In addition, a subgroup analy-
sis was performed in relatives under 45 years of follow-up
displaying similar results as the whole cohort (data not
shown). Finally, the diagnosis of AT, PC, and PS deﬁciencies
was based on plasma assays, not on DNA sequencing. Never-
theless, the genetic nature of the deﬁciency can be assumed
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from the presence of at least two affected members (includ-
ing the propositus) in the included families.
In conclusion, our results showed the impact of smoking
and obesity on the risk of VTE in families with inherited
thrombophilia. Taking into account common risk factors
(both environmental and genetics) for VTE in families with
inherited thrombophilia could be very helpful for assessing
individual risk, per se or in addition to the thrombophilia
testing. Independent and medico-economic studies are now
mandatory to validate and deﬁne the indications of the score.
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